To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(6 sites)

China

Sun Yat-sen Memorial Hospital,SunYat-sen University, Guangzhou, Guangdong

Tongji Hospital, Wuhan, Hubei

Hunan Cancer hospital, Changsha, Hunan

The first affiliated hospital with nanjing medical universtity, Nanjing, Jiangsu

West China Hospital, Chengdu, Sichuan

Tianjin Medical University Second Hospital, Tianjin, Tianjin Municipality